← FDA DRUG APPROVALS

FDA ANDA · ANDA204165

CLOPIDOGREL BISULFATE

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA204165
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-15
LATEST ACTION
2023-01-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CLOPIDOGREL BISULFATEPrescription
CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET · ORAL
CLOPIDOGREL BISULFATEPrescription
CLOPIDOGREL BISULFATE EQ 300MG BASE · TABLET · ORAL

Approval history

2023-01-23Labeling · Supplement 25 · standardAP
2022-03-31Labeling · Supplement 18 · standardAP
2019-12-13Labeling · Supplement 7 · standardAP
2019-12-13Labeling · Supplement 8 · standardAP
2019-12-13Labeling · Supplement 14 · standardAP
2019-12-13Labeling · Supplement 12 · standardAP
2019-12-13Labeling · Supplement 9 · standardAP
2019-12-13Labeling · Supplement 15 · standardAP
2016-05-10Labeling · Supplement 4 · standardAP
2014-09-15UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →